Form 424B3 iBio, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Chardan Comments on iBio, Inc. (IBIO)
June 25, 2025 7:58 AM EDTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $5.00 price target on iBio, Inc. (NASDAQ: IBIO)
The analyst comments "iBio has announced its third program to address obesity, an amylin agonist antibody, that's part of its collaboration with AstralBio (private). This amylin receptor agonist antibody has shown to decrease food intake in a mouse model of obesity by 60%, comparable to the 67% food intake reduction observed with a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide. Amylin is a 37 amino acid pancreatic peptide hormone secreted by the pancreas... More
